查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967585

人工智慧在心臟病學領域的市場－全球產業規模、佔有率、趨勢、機會、預測：按組件、應用、地區和競爭對手分類，2021-2031年

Artificial Intelligence in Cardiology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球人工智慧 (AI) 驅動的心臟病學市場預計將從 2025 年的 8.3887 億美元成長到 2031 年的 16.6556 億美元，複合年成長率達到 12.11%。

該領域利用機器學習演算法和計算分析來解讀複雜的心血管數據，從而促進疾病的早期發現並制定個人化的治療方案。推動該市場成長要素包括全球心臟病負擔的日益加重，以及隨著患者數量的成長而對簡化臨床工作流程的需求。此外，醫療專業人員對數位健康工具信心的增強也是推動成長的因素之一；根據美國醫學會 (AMA) 2024 年的報告，66% 的醫生在其診療實踐中使用醫療人工智慧，與上年度相比，採用率顯著提高。

市場概覽
預測期 2027-2031
市場規模：2025年 8.3887億美元
市場規模：2031年 16.6556億美元
複合年成長率：2026-2031年 12.11%
成長最快的細分市場 軟體解決方案
最大的市場 北美洲

然而，市場在資料隱私和嚴格的監管合規方面面臨許多挑戰。演算法訓練需要處理大量敏感的患者數據，這引發了安全隱患，並要求遵守嚴格的法律標準。這可能會延緩新解決方案的核准和部署。這些合規義務實際上減緩了創新步伐，並嚴重阻礙了這些先進診斷技術快速融入標準臨床護理。

市場促進因素

心血管疾病發生率的上升是推動心臟病學領域採用人工智慧的主要動力，也因此需要更先進的工具來應對日益成長的臨床和經濟負擔。隨著患者群體老化和心臟病複雜性的增加，醫療系統正在利用人工智慧實現診斷流程的自動化，降低誤診率，並減輕長期心臟護理成本的上升。美國心臟協會2024年6月發布的《預測2050年美國心血管疾病和中風負擔》建議強調了這一轉變的緊迫性，該報告預測，到2050年，心血管疾病總成本將成長兩倍，達到1.8兆美元。因此，醫院正積極採用人工智慧驅動的預測分析和影像解決方案，以最佳化資源分配，並在不相應增加醫護人員工作量的前提下改善病患預後。

同時，醫療人工智慧領域的投資和資金不斷增加，加速了專業心臟解決方案的開發和商業化，並降低了創新門檻。創業投資和政府津貼尤其著重於支持心臟病學這一高影響力領域，以推動能夠更精準地解讀心電圖和超音波心動圖的演算法研發。矽谷銀行2024年6月發布的報告《人工智慧驅動的醫療體驗》顯示，2024年初，人工智慧醫療公司獲得了28億美元的投資，其中一半的診斷投資成長都流向了心血管疾病領域。這筆資金的流入正在推動產品組合的快速擴張。正如MedTech Dive在2024年指出的那樣，心血管人工智慧是已通過核准技術中第二大類別，已有98種設備在美國FDA正式註冊，這表明該市場已趨於成熟，並正迅速從概念階段過渡到臨床應用階段。

市場挑戰

資料隱私和嚴格的監管合規是人工智慧在全球心臟病學領域擴張的主要障礙。開發高精度心血管演算法需要獲取大量敏感的患者資訊，包括高解析度圖像和基因組圖譜。然而，嚴格的資料保護法律體制要求複雜的匿名化流程和安全的基礎設施，這顯著增加了開發成本並延長了監管核准時間。這些合規負擔極大地減緩了新診斷工具進入市場的速度，並限制了臨床醫生能夠即時使用這些工具。

此外，資料外洩的風險促使醫療機構採取謹慎的態度，延後採用人工智慧整合系統。這種猶豫源於不當處理病患記錄可能帶來的法律和聲譽後果，這些後果往往超過了早期採用帶來的臨床益處。根據醫療資訊管理系統協會 (HIMSS) 預測，到 2025 年，75% 的醫療專業人員將把資料隱私視為採用人工智慧技術時的最大顧慮。這種對資料安全的普遍擔憂，加上醫療機構優先考慮風險規避而非在心臟科整合計算分析，正在直接阻礙市場成長。

市場趨勢

人工智慧與消費級穿戴裝置的融合，正在變革患者管理模式，使其從間歇性診斷轉向即時追蹤。先進的演算法透過分析市售智慧型手錶的數據，以醫療級靈敏度檢測心律不整和結構性心臟缺陷，從而將臨床監測直接延伸至日常生活。這項技術展現了利用非侵入性、消費者產生的數據制定預防性心臟照護策略的潛力，彌合了生活方式技術與臨床醫學之間的鴻溝。梅奧診所2025年5月發布的摘要《人工智慧在心血管醫學中的應用》指出，應用於穿戴式裝置數據的人工智慧輔助篩檢工具能夠以93%的準確率成功識別左心室功能障礙高風險族群，凸顯了消費級技術的巨大診斷潛力。

同時，人工智慧引導的機器人技術和導航在介入性心臟病學領域的應用，正在徹底改變導管介入手術的精確度。透過整合即時成像和預測性路徑規劃，人工智慧驅動的機器人系統使介入性心臟病專家能夠以亞毫米級的精度操控複雜的血管解剖結構，從而顯著降低醫療團隊的輻射暴露。隨著醫療機構尋求透過手術結果的標準化和自動化來提升安全性，這項技術正迅速獲得商業性認可。根據Stereotaxis公司於2025年3月發布的2024會計年度全年財務報告，新一代磁導航機器人系統的加速應用，使其第四季銷售額年增了39%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：心臟病學人工智慧的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按組件（硬體、軟體解決方案、服務）
    • 依應用領域（心律不整、中風、缺血性心臟疾病、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美心臟病學人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：人工智慧在歐洲心臟病學領域的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區心臟病學人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲心臟病學人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：人工智慧在南美洲心臟病學領域的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球心臟病學人工智慧市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • IDOVEN
  • Dia Imaging Analysis Ltd
  • Ultromics Limited
  • Tempus AI, Inc.
  • Koninklijke Philips NV
  • UltraSight Inc.
  • HeartVista Inc.
  • RSIP Vision
  • Cleerly, Inc.
  • Viz.ai, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23989

The Global Artificial Intelligence in Cardiology Market is projected to expand from USD 838.87 Million in 2025 to USD 1665.56 Million by 2031, achieving a CAGR of 12.11%. This sector utilizes machine learning algorithms and computational analytics to decipher complex cardiovascular data, thereby enhancing early disease detection and tailoring treatment plans. Key accelerators for this market include the rising global burden of heart conditions and the critical necessity to streamline clinical workflows amidst growing patient volumes. This growth trajectory is further bolstered by the increasing confidence of medical professionals in digital health tools, evidenced by the American Medical Association's 2024 report, which indicated that 66% of physicians utilized healthcare AI in their practice, marking a substantial rise in adoption compared to the prior year.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 838.87 Million
Market Size 2031USD 1665.56 Million
CAGR 2026-203112.11%
Fastest Growing SegmentSoftware Solutions
Largest MarketNorth America

However, the market confronts significant hurdles regarding data privacy and strict regulatory compliance. The requirement to process massive volumes of sensitive patient data for algorithm training triggers security concerns and mandates adherence to rigorous legal standards, which can delay the approval and deployment of new solutions. These compliance obligations effectively slow the pace of innovation, acting as a substantial impediment to the rapid integration of these advanced diagnostic technologies into standard clinical care.

Market Driver

The escalating prevalence of cardiovascular diseases acts as the primary catalyst for the adoption of artificial intelligence in cardiology, creating a demand for sophisticated tools to manage the growing clinical and economic strain. As patient populations age and heart conditions become more complex, healthcare systems are leveraging AI to automate diagnostic workflows, minimize error rates, and control the rising costs associated with long-term cardiac care. The urgency of this shift is underscored by the American Heart Association's June 2024 advisory, 'Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050', which projects that total cardiovascular-related costs will triple to $1.8 trillion by 2050. Consequently, hospitals are aggressively integrating AI-driven predictive analytics and imaging solutions to optimize resource allocation and improve patient outcomes without proportionally increasing staff workloads.

Simultaneously, rising investments and funding for healthcare AI are accelerating the development and commercialization of specialized cardiac solutions, lowering barriers to technological innovation. Venture capital and government grants are specifically targeting the high-impact potential of cardiology, driving R&D for algorithms capable of interpreting electrocardiograms and echocardiograms with enhanced accuracy. According to Silicon Valley Bank's 'AI-Powered Healthcare Experience' report from June 2024, $2.8 billion was invested in AI healthcare companies in early 2024, with half of the recent surge in diagnostic investment directed at cardiovascular disease. This influx of capital has translated into a rapidly expanding product landscape; as noted by MedTech Dive in 2024, cardiovascular AI represented the second-largest category of cleared technologies, with 98 devices officially listed by the U.S. FDA, signaling a maturing market moving quickly from concept to clinical deployment.

Market Challenge

Data privacy and strict regulatory compliance represent a significant barrier to the expansion of the Global Artificial Intelligence in Cardiology Market. Developing high-precision cardiovascular algorithms requires access to vast repositories of sensitive patient information, including high-resolution imaging and genomic profiles. However, stringent legal frameworks regarding data protection necessitate complex de-identification procedures and secure infrastructure, which substantially inflate development costs and prolong the time required for regulatory approval. These compliance burdens effectively decelerate the pace at which new diagnostic tools can be brought to market, limiting their immediate availability to clinicians.

Furthermore, the risk of data breaches fosters a cautious approach among healthcare institutions, delaying the procurement of AI-integrated systems. This hesitation is driven by the potential legal and reputational consequences of mishandling patient records, which often outweigh the perceived clinical benefits of early adoption. According to the Healthcare Information and Management Systems Society, in 2025, 75% of healthcare professionals identified data privacy as a top concern regarding the implementation of artificial intelligence technologies. This prevailing anxiety regarding data security directly impedes market growth, as medical facilities prioritize risk mitigation over the integration of computational analytics in cardiology departments.

Market Trends

The integration of AI with consumer wearables for continuous cardiac monitoring is reshaping patient management by shifting from episodic diagnostics to real-time tracking. Advanced algorithms now analyze data from commercial smartwatches to detect arrhythmias and structural heart defects with medical-grade sensitivity, extending clinical oversight directly into daily life. This capability validates the use of non-invasive, consumer-generated data for preemptive cardiac care strategies, bridging the gap between lifestyle technology and clinical medicine. According to the Mayo Clinic's May 2025 overview, 'Artificial Intelligence (AI) in Cardiovascular Medicine', an AI-assisted screening tool applied to wearable data successfully identified individuals at risk of left ventricular dysfunction 93% of the time, confirming the high diagnostic potential of consumer-facing technology.

Simultaneously, the adoption of AI-guided robotics and navigation in interventional cardiology is revolutionizing the precision of catheter-based procedures. By synthesizing real-time imaging with predictive path planning, AI-driven robotic systems allow interventionalists to navigate complex vascular anatomy with sub-millimeter accuracy while significantly reducing radiation exposure for the medical team. This technology is rapidly gaining commercial traction as healthcare facilities seek to standardize procedural outcomes and enhance safety through automation. According to Stereotaxis's '2024 Full Year Financial Results' report from March 2025, the company recorded a 39% year-over-year revenue increase in the fourth quarter, driven by the accelerating deployment of its next-generation robotic magnetic navigation systems.

Key Market Players

  • IDOVEN
  • Dia Imaging Analysis Ltd
  • Ultromics Limited
  • Tempus AI, Inc.
  • Koninklijke Philips N.V
  • UltraSight Inc.
  • HeartVista Inc.
  • RSIP Vision
  • Cleerly, Inc.
  • Viz.ai, Inc.

Report Scope

In this report, the Global Artificial Intelligence in Cardiology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Intelligence in Cardiology Market, By Component

  • Hardware
  • Software Solutions
  • Services

Artificial Intelligence in Cardiology Market, By Application

  • Cardiac Arrhythmias
  • Stroke
  • Ischemic Heart Disease /CAD
  • Others

Artificial Intelligence in Cardiology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Intelligence in Cardiology Market.

Available Customizations:

Global Artificial Intelligence in Cardiology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Artificial Intelligence in Cardiology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Component (Hardware, Software Solutions, Services)
    • 5.2.2. By Application (Cardiac Arrhythmias, Stroke, Ischemic Heart Disease /CAD, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Artificial Intelligence in Cardiology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Artificial Intelligence in Cardiology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Component
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Artificial Intelligence in Cardiology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Component
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Artificial Intelligence in Cardiology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Component
        • 6.3.3.2.2. By Application

7. Europe Artificial Intelligence in Cardiology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Artificial Intelligence in Cardiology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Application
    • 7.3.2. France Artificial Intelligence in Cardiology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Artificial Intelligence in Cardiology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Artificial Intelligence in Cardiology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Component
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Artificial Intelligence in Cardiology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Component
        • 7.3.5.2.2. By Application

8. Asia Pacific Artificial Intelligence in Cardiology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Artificial Intelligence in Cardiology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Application
    • 8.3.2. India Artificial Intelligence in Cardiology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Artificial Intelligence in Cardiology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Artificial Intelligence in Cardiology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Artificial Intelligence in Cardiology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Application

9. Middle East & Africa Artificial Intelligence in Cardiology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Artificial Intelligence in Cardiology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Artificial Intelligence in Cardiology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Artificial Intelligence in Cardiology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Application

10. South America Artificial Intelligence in Cardiology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Artificial Intelligence in Cardiology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Artificial Intelligence in Cardiology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Artificial Intelligence in Cardiology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Artificial Intelligence in Cardiology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. IDOVEN
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Dia Imaging Analysis Ltd
  • 15.3. Ultromics Limited
  • 15.4. Tempus AI, Inc.
  • 15.5. Koninklijke Philips N.V
  • 15.6. UltraSight Inc.
  • 15.7. HeartVista Inc.
  • 15.8. RSIP Vision
  • 15.9. Cleerly, Inc.
  • 15.10. Viz.ai, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer